Track topics on Twitter Track topics that are important to you
Data From Largest Oncology Pipeline in Company's History First-in-Human Data Evaluating Investigational AMG 510, the First KRASG12C Inhibitor to Reach Clinical Stage, in Solid Tumors Potential Versatility of BiTE® Immuno-oncology Platform Reinforced With Phase 1 Asset Updates THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundati...
Original Article: Amgen Showcases Oncology Pipeline At ASCO 2019NEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...